Search results
Showing 3051 to 3100 of 8238 results
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
This document contains advice to help you access treatments and care that NICE has recommended
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.
More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.
1 How do I control my blood pressure? Lifestyle options and choice of medicines Patient decision aid c NICE 2019. All rights reserved. Subject to...
This indicator has been updated and replaced by NICE indicator 322.
This indicator has been updated and replaced by NICE indicator 317.
This indicator has been updated and replaced by NICE indicator 317.
This indicator has been updated and replaced by NICE indicator 320.
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
Hypertension: confirming diagnosis with HBPM or ABPM (IND115)
This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66
This indicator covers the percentage of patients with dementia with the contact details of a named carer on their record. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM64
This indicator covers the percentage of patients with cancer diagnosed within the preceding 15 months who have a review recorded as occurring within 3 months of the practice receiving confirmation of the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM62
Cardiovascular disease prevention: cholesterol treatment target (secondary prevention)
This indicator has been updated and replaced by NICE indicator 278.
This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a test for haematuria in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM76
This indicator covers establishing and maintaining a register of patients with learning disabilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM73
Asthma. Patient decision aid on asthma inhalers and climate change (BTS, NICE, SIGN)
Asthma inhalers and climate change What is this decision aid about? Inhalers are a key part of treating your asthma. The most important thing is that...
1 Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer? Patient decision aid How likely am I to benefit? If you take...
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Surgery for vaginal vault prolapse Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last updated April 2019....
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Interim methods guide for developing service guidance 2014 (PMG8)
This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented
Medical technologies evaluation programme methods guide (PMG33)
This methods guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it
Medical technologies evaluation programme process guide (PMG34)
This process guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
Good practice guidance – Integrated process statement (PMG12)
This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
Interim clinical guideline surveillance process and methods guide 2013 (PMG16)
This guide outlines the main elements of the interim NICE clinical guideline surveillance process and methodology, which was agreed by the NICE Board in July 2013
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
View a complete list of indicators currently being developed. Our indicators measure outcomes that reflect the quality of care or processes.
This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources
This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders
Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)
This guide sets out the process and methods used to develop rapid guidelines on COVID-19
Processes and methods for NICE-wide guidance surveillance (PMG49)
This guide describes the methods and processes that NICE follows to assess the impact of new evidence, changes to the health and care system, or other new, relevant information that has come to light after NICE guidance has published